APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pharmacodynamic Biomarker Assay

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Pharmacodynamic Biomarker Assay Market Analysis and Forecast 2026-2032

2 May 2026221 pages

Choose your research edition.

Industry ResearchPharmacodynamic Biomarker Assay Industry Research Report 2026112 pages · $2,950 USDIndustry Growth & TrendsGlobal Pharmacodynamic Biomarker Assay Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Pharmacodynamic Biomarker Assay Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pharmacodynamic Biomarker Assay Market Outlook and Growth Opportunities 2026182 pages · $4,250 USDMarket Analysis & ForecastGlobal Pharmacodynamic Biomarker Assay Market Analysis and Forecast 2026-2032221 pages · $4,950 USD

Market perspective

The global Pharmacodynamic Biomarker Assay market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Pharmacodynamic Biomarker Assay is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Pharmacodynamic Biomarker Assay is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Pharmacodynamic Biomarker Assay is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Pharmacodynamic Biomarker Assay is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Pharmacodynamic Biomarker Assay include Thermo Fisher Scientific, Merck, Bio-Rad Laboratories, QIAGEN, Roche, Danaher Corporation, Siemens Healthcare, Abbott and Agilent Technologies, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Pharmacodynamic Biomarker Assay, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Pharmacodynamic Biomarker Assay, also provides the revenue of main regions and countries. Of the upcoming market potential for Pharmacodynamic Biomarker Assay, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Pharmacodynamic Biomarker Assay revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Pharmacodynamic Biomarker Assay market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Pharmacodynamic Biomarker Assay revenue, projected growth trends, production technology, application and end-user industry.

Pharmacodynamic Biomarker Assay Segment by Company

Thermo Fisher Scientific

Merck

Bio-Rad Laboratories

QIAGEN

Roche

Danaher Corporation

Siemens Healthcare

Abbott

Agilent Technologies

Pharmacodynamic Biomarker Assay Segment by Type

Exposure Biomarkers

Effect Biomarkers

Susceptibility Biomarkers

Pharmacodynamic Biomarker Assay Segment by Application

Diagnostics

Drug Discovery

Personalized Medicine

Others

Pharmacodynamic Biomarker Assay Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pharmacodynamic Biomarker Assay market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pharmacodynamic Biomarker Assay and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pharmacodynamic Biomarker Assay.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Pharmacodynamic Biomarker Assay in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Pharmacodynamic Biomarker Assay company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Pharmacodynamic Biomarker Assay revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Pharmacodynamic Biomarker Assay Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Exposure Biomarkers Major Player Table 3. Effect Biomarkers Major Player Table 4. Susceptibility Biomarkers Major Player Table 5. Global Pharmacodynamic Biomarker Assay Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Diagnostics Major Player Table 7. Drug Discovery Major Player Table 8. Personalized Medicine Major Player Table 9. Others Major Player Table 10. Pharmacodynamic Biomarker Assay Industry Trends Table 11. Pharmacodynamic Biomarker Assay Industry Drivers Table 12. Pharmacodynamic Biomarker Assay Industry Opportunities and Challenges Table 13. Pharmacodynamic Biomarker Assay Industry Restraints Table 14. Global Pharmacodynamic Biomarker Assay Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Pharmacodynamic Biomarker Assay Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Pharmacodynamic Biomarker Assay Market Share by Region (2021-2026) Table 17. Global Pharmacodynamic Biomarker Assay Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Pharmacodynamic Biomarker Assay Market Share by Region (2027-2032) Table 19. Global Pharmacodynamic Biomarker Assay Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Pharmacodynamic Biomarker Assay Revenue Market Share by Players (2021-2026) Table 21. Global Pharmacodynamic Biomarker Assay Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Pharmacodynamic Biomarker Assay Key Players Headquarters & Area Served Table 23. Global Pharmacodynamic Biomarker Assay Players, Product Type & Application Table 24. Global Pharmacodynamic Biomarker Assay Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Pharmacodynamic Biomarker Assay by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Pharmacodynamic Biomarker Assay Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Pharmacodynamic Biomarker Assay Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Pharmacodynamic Biomarker Assay Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Pharmacodynamic Biomarker Assay Revenue Market Share by Type (2021-2026) Table 31. Global Pharmacodynamic Biomarker Assay Revenue Market Share by Type (2027-2032) Table 32. Global Pharmacodynamic Biomarker Assay Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Pharmacodynamic Biomarker Assay Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Pharmacodynamic Biomarker Assay Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Pharmacodynamic Biomarker Assay Revenue Market Share by Application (2021-2026) Table 36. Global Pharmacodynamic Biomarker Assay Revenue Market Share by Application (2027-2032) Table 37. Thermo Fisher Scientific Company Information Table 38. Thermo Fisher Scientific Business Overview Table 39. Thermo Fisher Scientific Pharmacodynamic Biomarker Assay Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Thermo Fisher Scientific Pharmacodynamic Biomarker Assay Product Portfolio Table 41. Thermo Fisher Scientific Recent Development Table 42. Merck Company Information Table 43. Merck Business Overview Table 44. Merck Pharmacodynamic Biomarker Assay Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Merck Pharmacodynamic Biomarker Assay Product Portfolio Table 46. Merck Recent Development Table 47. Bio-Rad Laboratories Company Information Table 48. Bio-Rad Laboratories Business Overview Table 49. Bio-Rad Laboratories Pharmacodynamic Biomarker Assay Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Bio-Rad Laboratories Pharmacodynamic Biomarker Assay Product Portfolio Table 51. Bio-Rad Laboratories Recent Development Table 52. QIAGEN Company Information Table 53. QIAGEN Business Overview Table 54. QIAGEN Pharmacodynamic Biomarker Assay Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. QIAGEN Pharmacodynamic Biomarker Assay Product Portfolio Table 56. QIAGEN Recent Development Table 57. Roche Company Information Table 58. Roche Business Overview Table 59. Roche Pharmacodynamic Biomarker Assay Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Roche Pharmacodynamic Biomarker Assay Product Portfolio Table 61. Roche Recent Development Table 62. Danaher Corporation Company Information Table 63. Danaher Corporation Business Overview Table 64. Danaher Corporation Pharmacodynamic Biomarker Assay Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Danaher Corporation Pharmacodynamic Biomarker Assay Product Portfolio Table 66. Danaher Corporation Recent Development Table 67. Siemens Healthcare Company Information Table 68. Siemens Healthcare Business Overview Table 69. Siemens Healthcare Pharmacodynamic Biomarker Assay Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Siemens Healthcare Pharmacodynamic Biomarker Assay Product Portfolio Table 71. Siemens Healthcare Recent Development Table 72. Abbott Company Information Table 73. Abbott Business Overview Table 74. Abbott Pharmacodynamic Biomarker Assay Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Abbott Pharmacodynamic Biomarker Assay Product Portfolio Table 76. Abbott Recent Development Table 77. Agilent Technologies Company Information Table 78. Agilent Technologies Business Overview Table 79. Agilent Technologies Pharmacodynamic Biomarker Assay Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Agilent Technologies Pharmacodynamic Biomarker Assay Product Portfolio Table 81. Agilent Technologies Recent Development Table 82. North America Pharmacodynamic Biomarker Assay Revenue by Type (2021-2026) & (US$ Million) Table 83. North America Pharmacodynamic Biomarker Assay Revenue by Type (2027-2032) & (US$ Million) Table 84. North America Pharmacodynamic Biomarker Assay Revenue by Application (2021-2026) & (US$ Million) Table 85. North America Pharmacodynamic Biomarker Assay Revenue by Application (2027-2032) & (US$ Million) Table 86. North America Pharmacodynamic Biomarker Assay Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 87. North America Pharmacodynamic Biomarker Assay Revenue by Country (2021-2026) & (US$ Million) Table 88. North America Pharmacodynamic Biomarker Assay Revenue by Country (US$ Million) & (2027-2032) Table 89. Europe Pharmacodynamic Biomarker Assay Revenue by Type (2021-2026) & (US$ Million) Table 90. Europe Pharmacodynamic Biomarker Assay Revenue by Type (2027-2032) & (US$ Million) Table 91. Europe Pharmacodynamic Biomarker Assay Revenue by Application (2021-2026) & (US$ Million) Table 92. Europe Pharmacodynamic Biomarker Assay Revenue by Application (2027-2032) & (US$ Million) Table 93. Europe Pharmacodynamic Biomarker Assay Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 94. Europe Pharmacodynamic Biomarker Assay Revenue by Country (2021-2026) & (US$ Million) Table 95. Europe Pharmacodynamic Biomarker Assay Revenue by Country (US$ Million) & (2027-2032) Table 96. China Pharmacodynamic Biomarker Assay Revenue by Type (2021-2026) & (US$ Million) Table 97. China Pharmacodynamic Biomarker Assay Revenue by Type (2027-2032) & (US$ Million) Table 98. China Pharmacodynamic Biomarker Assay Revenue by Application (2021-2026) & (US$ Million) Table 99. China Pharmacodynamic Biomarker Assay Revenue by Application (2027-2032) & (US$ Million) Table 100. Asia Pharmacodynamic Biomarker Assay Revenue by Type (2021-2026) & (US$ Million) Table 101. Asia Pharmacodynamic Biomarker Assay Revenue by Type (2027-2032) & (US$ Million) Table 102. Asia Pharmacodynamic Biomarker Assay Revenue by Application (2021-2026) & (US$ Million) Table 103. Asia Pharmacodynamic Biomarker Assay Revenue by Application (2027-2032) & (US$ Million) Table 104. Asia Pharmacodynamic Biomarker Assay Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 105. Asia Pharmacodynamic Biomarker Assay Revenue by Region (US$ Million) & (2021-2026) Table 106. Asia Pharmacodynamic Biomarker Assay Revenue by Region (US$ Million) & (2027-2032) Table 107. SAMEA Pharmacodynamic Biomarker Assay Revenue by Type (2021-2026) & (US$ Million) Table 108. SAMEA Pharmacodynamic Biomarker Assay Revenue by Type (2027-2032) & (US$ Million) Table 109. SAMEA Pharmacodynamic Biomarker Assay Revenue by Application (2021-2026) & (US$ Million) Table 110. SAMEA Pharmacodynamic Biomarker Assay Revenue by Application (2027-2032) & (US$ Million) Table 111. SAMEA Pharmacodynamic Biomarker Assay Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 112. SAMEA Pharmacodynamic Biomarker Assay Revenue by Country (2021-2026) & (US$ Million) Table 113. SAMEA Pharmacodynamic Biomarker Assay Revenue by Country (US$ Million) & (2027-2032) Table 114. Research Programs/Design for This Report Table 115. Authors List of This Report Table 116. Secondary Sources Table 117. Primary Sources List of Figures Figure 1. Pharmacodynamic Biomarker Assay Image Figure 2. Global Pharmacodynamic Biomarker Assay Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pharmacodynamic Biomarker Assay Market Size Share 2021 VS 2025 VS 2032 Figure 4. Exposure Biomarkers Image Figure 5. Effect Biomarkers Image Figure 6. Susceptibility Biomarkers Image Figure 7. Global Pharmacodynamic Biomarker Assay Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Pharmacodynamic Biomarker Assay Market Size Share 2021 VS 2025 VS 2032 Figure 9. Diagnostics Image Figure 10. Drug Discovery Image Figure 11. Personalized Medicine Image Figure 12. Others Image Figure 13. Global Pharmacodynamic Biomarker Assay Market Size (US$ Million) & (2021-2032) Figure 14. Global Pharmacodynamic Biomarker Assay Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Pharmacodynamic Biomarker Assay Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Pharmacodynamic Biomarker Assay Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Pharmacodynamic Biomarker Assay Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Pharmacodynamic Biomarker Assay Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Pharmacodynamic Biomarker Assay Revenue Market Share by Type (2021-2032) Figure 21. Global Pharmacodynamic Biomarker Assay Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Pharmacodynamic Biomarker Assay Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Pharmacodynamic Biomarker Assay Revenue Market Share by Application (2021-2032) Figure 24. North America Pharmacodynamic Biomarker Assay Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Pharmacodynamic Biomarker Assay Revenue Share by Type (2021-2032) Figure 26. North America Pharmacodynamic Biomarker Assay Revenue Share by Application (2021-2032) Figure 27. North America Pharmacodynamic Biomarker Assay Revenue Share by Country (2021-2032) Figure 28. United States Pharmacodynamic Biomarker Assay Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Pharmacodynamic Biomarker Assay Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Pharmacodynamic Biomarker Assay Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Pharmacodynamic Biomarker Assay Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Pharmacodynamic Biomarker Assay Revenue Share by Type (2021-2032) Figure 33. Europe Pharmacodynamic Biomarker Assay Revenue Share by Application (2021-2032) Figure 34. Europe Pharmacodynamic Biomarker Assay Revenue Share by Country (2021-2032) Figure 35. Germany Pharmacodynamic Biomarker Assay Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Pharmacodynamic Biomarker Assay Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Pharmacodynamic Biomarker Assay Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Pharmacodynamic Biomarker Assay Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Pharmacodynamic Biomarker Assay Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Pharmacodynamic Biomarker Assay Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Pharmacodynamic Biomarker Assay Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Pharmacodynamic Biomarker Assay Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Pharmacodynamic Biomarker Assay Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Pharmacodynamic Biomarker Assay Revenue Share by Type (2021-2032) Figure 45. China Pharmacodynamic Biomarker Assay Revenue Share by Application (2021-2032) Figure 46. Asia Pharmacodynamic Biomarker Assay Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Pharmacodynamic Biomarker Assay Revenue Share by Type (2021-2032) Figure 48. Asia Pharmacodynamic Biomarker Assay Revenue Share by Application (2021-2032) Figure 49. Asia Pharmacodynamic Biomarker Assay Revenue Share by Region (2021-2032) Figure 50. Japan Pharmacodynamic Biomarker Assay Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Pharmacodynamic Biomarker Assay Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Pharmacodynamic Biomarker Assay Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Pharmacodynamic Biomarker Assay Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Pharmacodynamic Biomarker Assay Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Pharmacodynamic Biomarker Assay Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Pharmacodynamic Biomarker Assay Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Pharmacodynamic Biomarker Assay Revenue Share by Type (2021-2032) Figure 58. SAMEA Pharmacodynamic Biomarker Assay Revenue Share by Application (2021-2032) Figure 59. SAMEA Pharmacodynamic Biomarker Assay Revenue Share by Country (2021-2032) Figure 60. Brazil Pharmacodynamic Biomarker Assay Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Pharmacodynamic Biomarker Assay Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Pharmacodynamic Biomarker Assay Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Pharmacodynamic Biomarker Assay Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Pharmacodynamic Biomarker Assay Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Pharmacodynamic Biomarker Assay Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Pharmacodynamic Biomarker Assay Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Pharmacodynamic Biomarker Assay Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Pharmacodynamic Biomarker Assay Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Pharmacodynamic Biomarker Assay Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Pharmacodynamic Biomarker Assay Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Exposure Biomarkers
  • Effect Biomarkers
  • Susceptibility Biomarkers
Applications
  • Diagnostics
  • Drug Discovery
  • Personalized Medicine
  • Others
Companies covered
  • Thermo Fisher Scientific
  • Merck
  • Bio-Rad Laboratories
  • QIAGEN
  • Roche
  • Danaher Corporation
  • Siemens Healthcare
  • Abbott
  • Agilent Technologies

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Pharmacodynamic Biomarker Assay Market by Type
  3. 1.2.1 Global Pharmacodynamic Biomarker Assay Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Exposure Biomarkers
  5. 1.2.3 Effect Biomarkers
  6. 1.2.4 Susceptibility Biomarkers
  7. 1.3 Pharmacodynamic Biomarker Assay Market by Application
  8. 1.3.1 Global Pharmacodynamic Biomarker Assay Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Diagnostics
  10. 1.3.3 Drug Discovery
  11. 1.3.4 Personalized Medicine
  12. 1.3.5 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Pharmacodynamic Biomarker Assay Market Dynamics
  1. 2.1 Pharmacodynamic Biomarker Assay Industry Trends
  2. 2.2 Pharmacodynamic Biomarker Assay Industry Drivers
  3. 2.3 Pharmacodynamic Biomarker Assay Industry Opportunities and Challenges
  4. 2.4 Pharmacodynamic Biomarker Assay Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Pharmacodynamic Biomarker Assay Market Perspective (2021-2032)
  2. 3.2 Global Pharmacodynamic Biomarker Assay Growth Trends by Region
  3. 3.2.1 Global Pharmacodynamic Biomarker Assay Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Pharmacodynamic Biomarker Assay Market Size by Region (2021-2026)
  5. 3.2.3 Global Pharmacodynamic Biomarker Assay Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Pharmacodynamic Biomarker Assay Revenue by Players
  2. 4.1.1 Global Pharmacodynamic Biomarker Assay Revenue by Players (2021-2026)
  3. 4.1.2 Global Pharmacodynamic Biomarker Assay Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Pharmacodynamic Biomarker Assay Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Pharmacodynamic Biomarker Assay Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Pharmacodynamic Biomarker Assay Key Players Headquarters & Area Served
  7. 4.4 Global Pharmacodynamic Biomarker Assay Players, Product Type & Application
  8. 4.5 Global Pharmacodynamic Biomarker Assay Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Pharmacodynamic Biomarker Assay Market CR5 and HHI
  11. 4.6.3 2025 Pharmacodynamic Biomarker Assay Tier 1, Tier 2, and Tier 3
5 Pharmacodynamic Biomarker Assay Market Size by Type
  1. 5.1 Global Pharmacodynamic Biomarker Assay Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Pharmacodynamic Biomarker Assay Revenue by Type (2021-2032)
  3. 5.3 Global Pharmacodynamic Biomarker Assay Revenue Market Share by Type (2021-2032)
6 Pharmacodynamic Biomarker Assay Market Size by Application
  1. 6.1 Global Pharmacodynamic Biomarker Assay Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Pharmacodynamic Biomarker Assay Revenue by Application (2021-2032)
  3. 6.3 Global Pharmacodynamic Biomarker Assay Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Thermo Fisher Scientific
  2. 7.1.1 Thermo Fisher Scientific Company Information
  3. 7.1.2 Thermo Fisher Scientific Business Overview
  4. 7.1.3 Thermo Fisher Scientific Pharmacodynamic Biomarker Assay Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Thermo Fisher Scientific Pharmacodynamic Biomarker Assay Product Portfolio
  6. 7.1.5 Thermo Fisher Scientific Recent Developments
  7. 7.2 Merck
  8. 7.2.1 Merck Company Information
  9. 7.2.2 Merck Business Overview
  10. 7.2.3 Merck Pharmacodynamic Biomarker Assay Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Merck Pharmacodynamic Biomarker Assay Product Portfolio
  12. 7.2.5 Merck Recent Developments
  13. 7.3 Bio-Rad Laboratories
  14. 7.3.1 Bio-Rad Laboratories Company Information
  15. 7.3.2 Bio-Rad Laboratories Business Overview
  16. 7.3.3 Bio-Rad Laboratories Pharmacodynamic Biomarker Assay Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Bio-Rad Laboratories Pharmacodynamic Biomarker Assay Product Portfolio
  18. 7.3.5 Bio-Rad Laboratories Recent Developments
  19. 7.4 QIAGEN
  20. 7.4.1 QIAGEN Company Information
  21. 7.4.2 QIAGEN Business Overview
  22. 7.4.3 QIAGEN Pharmacodynamic Biomarker Assay Revenue and Gross Margin (2021-2026)
  23. 7.4.4 QIAGEN Pharmacodynamic Biomarker Assay Product Portfolio
  24. 7.4.5 QIAGEN Recent Developments
  25. 7.5 Roche
  26. 7.5.1 Roche Company Information
  27. 7.5.2 Roche Business Overview
  28. 7.5.3 Roche Pharmacodynamic Biomarker Assay Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Roche Pharmacodynamic Biomarker Assay Product Portfolio
  30. 7.5.5 Roche Recent Developments
  31. 7.6 Danaher Corporation
  32. 7.6.1 Danaher Corporation Company Information
  33. 7.6.2 Danaher Corporation Business Overview
  34. 7.6.3 Danaher Corporation Pharmacodynamic Biomarker Assay Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Danaher Corporation Pharmacodynamic Biomarker Assay Product Portfolio
  36. 7.6.5 Danaher Corporation Recent Developments
  37. 7.7 Siemens Healthcare
  38. 7.7.1 Siemens Healthcare Company Information
  39. 7.7.2 Siemens Healthcare Business Overview
  40. 7.7.3 Siemens Healthcare Pharmacodynamic Biomarker Assay Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Siemens Healthcare Pharmacodynamic Biomarker Assay Product Portfolio
  42. 7.7.5 Siemens Healthcare Recent Developments
  43. 7.8 Abbott
  44. 7.8.1 Abbott Company Information
  45. 7.8.2 Abbott Business Overview
  46. 7.8.3 Abbott Pharmacodynamic Biomarker Assay Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Abbott Pharmacodynamic Biomarker Assay Product Portfolio
  48. 7.8.5 Abbott Recent Developments
  49. 7.9 Agilent Technologies
  50. 7.9.1 Agilent Technologies Company Information
  51. 7.9.2 Agilent Technologies Business Overview
  52. 7.9.3 Agilent Technologies Pharmacodynamic Biomarker Assay Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Agilent Technologies Pharmacodynamic Biomarker Assay Product Portfolio
  54. 7.9.5 Agilent Technologies Recent Developments
8 North America
  1. 8.1 North America Pharmacodynamic Biomarker Assay Revenue (2021-2032)
  2. 8.2 North America Pharmacodynamic Biomarker Assay Revenue by Type (2021-2032)
  3. 8.2.1 North America Pharmacodynamic Biomarker Assay Revenue by Type (2021-2026)
  4. 8.2.2 North America Pharmacodynamic Biomarker Assay Revenue by Type (2027-2032)
  5. 8.3 North America Pharmacodynamic Biomarker Assay Revenue Share by Type (2021-2032)
  6. 8.4 North America Pharmacodynamic Biomarker Assay Revenue by Application (2021-2032)
  7. 8.4.1 North America Pharmacodynamic Biomarker Assay Revenue by Application (2021-2026)
  8. 8.4.2 North America Pharmacodynamic Biomarker Assay Revenue by Application (2027-2032)
  9. 8.5 North America Pharmacodynamic Biomarker Assay Revenue Share by Application (2021-2032)
  10. 8.6 North America Pharmacodynamic Biomarker Assay Revenue by Country
  11. 8.6.1 North America Pharmacodynamic Biomarker Assay Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Pharmacodynamic Biomarker Assay Revenue by Country (2021-2026)
  13. 8.6.3 North America Pharmacodynamic Biomarker Assay Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Pharmacodynamic Biomarker Assay Revenue (2021-2032)
  2. 9.2 Europe Pharmacodynamic Biomarker Assay Revenue by Type (2021-2032)
  3. 9.2.1 Europe Pharmacodynamic Biomarker Assay Revenue by Type (2021-2026)
  4. 9.2.2 Europe Pharmacodynamic Biomarker Assay Revenue by Type (2027-2032)
  5. 9.3 Europe Pharmacodynamic Biomarker Assay Revenue Share by Type (2021-2032)
  6. 9.4 Europe Pharmacodynamic Biomarker Assay Revenue by Application (2021-2032)
  7. 9.4.1 Europe Pharmacodynamic Biomarker Assay Revenue by Application (2021-2026)
  8. 9.4.2 Europe Pharmacodynamic Biomarker Assay Revenue by Application (2027-2032)
  9. 9.5 Europe Pharmacodynamic Biomarker Assay Revenue Share by Application (2021-2032)
  10. 9.6 Europe Pharmacodynamic Biomarker Assay Revenue by Country
  11. 9.6.1 Europe Pharmacodynamic Biomarker Assay Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Pharmacodynamic Biomarker Assay Revenue by Country (2021-2026)
  13. 9.6.3 Europe Pharmacodynamic Biomarker Assay Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Pharmacodynamic Biomarker Assay Revenue (2021-2032)
  2. 10.2 China Pharmacodynamic Biomarker Assay Revenue by Type (2021-2032)
  3. 10.2.1 China Pharmacodynamic Biomarker Assay Revenue by Type (2021-2026)
  4. 10.2.2 China Pharmacodynamic Biomarker Assay Revenue by Type (2027-2032)
  5. 10.3 China Pharmacodynamic Biomarker Assay Revenue Share by Type (2021-2032)
  6. 10.4 China Pharmacodynamic Biomarker Assay Revenue by Application (2021-2032)
  7. 10.4.1 China Pharmacodynamic Biomarker Assay Revenue by Application (2021-2026)
  8. 10.4.2 China Pharmacodynamic Biomarker Assay Revenue by Application (2027-2032)
  9. 10.5 China Pharmacodynamic Biomarker Assay Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Pharmacodynamic Biomarker Assay Revenue (2021-2032)
  2. 11.2 Asia Pharmacodynamic Biomarker Assay Revenue by Type (2021-2032)
  3. 11.2.1 Asia Pharmacodynamic Biomarker Assay Revenue by Type (2021-2026)
  4. 11.2.2 Asia Pharmacodynamic Biomarker Assay Revenue by Type (2027-2032)
  5. 11.3 Asia Pharmacodynamic Biomarker Assay Revenue Share by Type (2021-2032)
  6. 11.4 Asia Pharmacodynamic Biomarker Assay Revenue by Application (2021-2032)
  7. 11.4.1 Asia Pharmacodynamic Biomarker Assay Revenue by Application (2021-2026)
  8. 11.4.2 Asia Pharmacodynamic Biomarker Assay Revenue by Application (2027-2032)
  9. 11.5 Asia Pharmacodynamic Biomarker Assay Revenue Share by Application (2021-2032)
  10. 11.6 Asia Pharmacodynamic Biomarker Assay Revenue by Country
  11. 11.6.1 Asia Pharmacodynamic Biomarker Assay Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Pharmacodynamic Biomarker Assay Revenue by Country (2021-2026)
  13. 11.6.3 Asia Pharmacodynamic Biomarker Assay Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Pharmacodynamic Biomarker Assay Revenue (2021-2032)
  2. 12.2 SAMEA Pharmacodynamic Biomarker Assay Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Pharmacodynamic Biomarker Assay Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Pharmacodynamic Biomarker Assay Revenue by Type (2027-2032)
  5. 12.3 SAMEA Pharmacodynamic Biomarker Assay Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Pharmacodynamic Biomarker Assay Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Pharmacodynamic Biomarker Assay Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Pharmacodynamic Biomarker Assay Revenue by Application (2027-2032)
  9. 12.5 SAMEA Pharmacodynamic Biomarker Assay Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Pharmacodynamic Biomarker Assay Revenue by Country
  11. 12.6.1 SAMEA Pharmacodynamic Biomarker Assay Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Pharmacodynamic Biomarker Assay Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Pharmacodynamic Biomarker Assay Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst